The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ILD with a granulomatous component
Publications
[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?].
Revue des maladies respiratoires 2012 Jan;29;64-9 — 2012 Jan — 64-9
Pulmonary toxicity associated with sirolimus treatment in kidney transplantation.
Transplantation proceedings 2006 Oct;38;2438-40 — 2006 Oct — 2438-40
Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.
Chest 2006 Jun;129;1718-21 — 2006 Jun — 1718-21
Patterns of pulmonary complications associated with sirolimus.
Respiration; international review of thoracic diseases 2006;73;367-74 — 2006 — 367-74
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
Transplantation 2001 Sep 15;72;787-90 — 2001 Sep 15 — 787-90